Email to colleague

Insert your email (required)


Comments


Insert email of your colleague (required)

Clinical 411 - CME Information

To proceed to the answer you have selected,
please review the following information and
click on the submit button at the end of this page.

CME-Certified Enduring Internet Activity

Jointly Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ) Center for Continuing and Outreach Education and Medicor Learning.

This educational activity is supported by an independent medical educational grant from Shire.

Ulcerative Colitis Management Series Learning Objective

During consultations, which factors need to be explored in order to effectively support adherence, and how should information and education be delivered?
Upon completion of this activity, participants should be able to recognize risk factors for non-adherence and identify strategies to improve patient adherence with prescribed medical therapies.

Credit Availability
Release Date: July 15, 2011 - Expiration Date: July 15, 2012

Program Description
Clinical411 is a dynamic, online educational platform that provides easy and immediate access to evidence-based answers from experts to current clinical questions physicians are facing in their practice. Unlike lengthy traditional programs, Clinical411 has been created with busy schedules in mind, allowing learners to select specific questions and receive expert answers that are practical and concise. Each answer is no more than 15 minutes in duration and is offered in various downloadable formats, including video, audio, and print. Learners are also eligible to receive 0.25 AMA PRA Category 1 Credits™ for each answer accessed which are then tracked and filed by the Clinical411 system.

Statement of Need and Overall Goal
In the treatment of challenging diseases like ulcerative colitis (UC), clinicians need to know how to integrate research advances into every day practice in order to improve patient care and outcomes. However, many clinicians are failing to achieve response and remission, and avoid disease flares and complications in a significant number of their patients being managed for UC. UC accounts for 250,000 physician visits, 30,000 hospitalizations, and loss of more than one million workdays each year. The treatment of UC remains challenging; each patient is different and no single treatment is universally effective. Physicians must customize treatment regimens to meet each patient's unique needs. UC is typically managed by internists, particularly those with a subspecialty in gastroenterology. Two important topics these clinicians are currently confronting include how to maximize and maintain response to treatment and the challenge of improving the high rate of patient non-adherence to medication regimens.
To address this, this Clinical411 activity will provide evidence-based answers to important clinical questions related to the effective management of UC.

Target Audience
This educational activity is intended for gastroenterologists and internists. Other healthcare professionals involved in the management of patients with UC may also participate.

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ-Center for Continuing and Outreach Education and Medicor Learning. UMDNJ-Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.

UMDNJ-Center for Continuing and Outreach Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The estimated time to complete this activity is 15 minutes.

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, UMDNJ-CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by Steven R. Peikin, MD and pilot-tested for time required for participation by Kinshasa Morton, MD; Adam Palance, MD; and Adam Peyton, MD.

How to Receive Credit
To be eligible for CME credit, participants must review the activity, answer the post-test question correctly, and submit the online CME post-test and evaluation form. Participants will have the option to download or print their CME certificate instantly.

CME Activity Director
Steven R. Peikin, MD
Professor of Medicine
Robert Wood Johnson School of Medicine;
Head, Division of Gastroenterology & Liver Diseases
Cooper Hospital/University Medical Center
Camden, New Jersey

Disclosure Policy
In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-healthcare related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Faculty
Russell D. Cohen, MD, has disclosed the following relevant financial relationships. Consultant: Abbott, Advogent Group, Axcan Scandipharm, Centocor, Elan Pharmaceuticals, Guidepoint Global Consulting, Millennium Pharmaceuticals/Takeda, Prometheus Labs, Salix Pharmaceuticals, sanofi-aventis, Shire Pharmaceuticals, Tactical Advantage Group, and Warner-Chilcott; Speakers Bureau: Abbott, Merck Sharp and Dohme Farmaceutica/Merck Brazil, and Schering-Plough/Merck Mexico.

David T. Rubin, MD, has disclosed the following relevant financial relationships. Grant Support: Procter and Gamble Pharmaceuticals/Warner Chilcott, Salix Pharmaceuticals, and Prometheus Labs; Grant Support (registry): Abbott Immunology and Elan Pharmaceuticals; Consultant for Abbott Immunology, Centocor, Elan Pharmaceuticals, Given, Optimer Pharmaceuticals, Prometheus Labs, Salix Pharmaceuticals, Schering-Plough/Merck, Shire Pharmaceuticals, Millennium Pharmaceuticals/Takeda, and UCB Pharma; Speakers Bureau Schering-Plough/Merck; Co-Founder: Cornerstones Health, Inc., a non-profit medical education company.

CME Activity Director
Steven R. Peikin, MD has no relevant financial relationships to disclose.

Field Testers
Kinshasa Morton, MD; Adam Palance, MD; and Adam Peyton, MD have no relevant financial relationships to disclose.

Planners
UMDNJ-Center for Continuing and Outreach Education staff members, Patrick Dwyer, Director, Continuing Medical Education; Elizabeth S. Ward, Assistant Director, CME Compliance; and Felicia James, Program Manager, have no relevant financial relationships to disclose.

Medicor Learning staff members, David A. DePinho, General Manager; Wendy Gloffke, PhD, Medical Director; and John J.D. Juchniewicz, MCIS, Director of Education and Compliance, have no relevant financial relationships to disclose.

Off-Label Disclosure Statement
This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Content Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of UMDNJ, Medicor Learning or any manufacturer of pharmaceuticals or devices. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the faculty. Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity.

© 2011 UMDNJ-Center for Continuing and Outreach Education and Medicor Learning, LLC.
All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education and Medicor Learning.

Privacy Policy
To view UMDNJ's privacy policy, please visit http://ccoe.umdnj.edu/general/privacypolicy.html
To view Medicor Learning's privacy policy, please visit http://www.medicorlearning.com/Privacy_Statement.html

Hardware/Software Requirements
Clinical411 is accessible using the following browsers: Internet Explorer 6.x or higher, Firefox 2.x or higher, Safari 2.x or higher. Educational activities may require additional software to view multimedia, presentation or printable versions of their content. That software may be: Macromedia Flash, Adobe Acrobat, or Microsoft PowerPoint.

Contact
For further information about this and other Clinical411 programs contact:
Clinical411@medicorlearning.com or Medicor Learning, LLC, 295 Princeton Hightstown Road, Unit 118, West Windsor, NJ 08550.

For CME information or other concerns contact UMDNJ-CCOE at: ccoe@umdnj.edu or 973-972-4267.